Sagent Pharmaceuticals,
Inc. SGNT today announced the launch of Atracurium Besylate
Injection, USP, the generic form of the neuromuscular blocker Tracrium®, in 50
mg per 5 mL latex-free vials. According to IMS data for the twelve-months
ended March 2012, the U.S. market for Atracurium approximated $2.4 million. As
with all products in Sagent's portfolio, Atracurium features the company's
PreventIV Measures^SM packaging and labeling designed to aid in the reduction
of medication errors.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in